It's been 50-years since war was declared on cancer, and there has been no effective therapy, treatment, or cure that has gotten us any closer to that world where we no longer fear cancer. But we can get there. It takes effort. And it takes a lot of money.
Our scientists at the University of Southern California Norris Cancer Center discovered a novel drug. When we tested it on six of the most aggressive cancers: ovarian, breast, prostate, prostate bone metastasis, melanoma, and brain cancer, we found it reduces tumor growth and progression by 90%. And we are starting to prove that the drug affects how cancer spreads throughout the body and may affect metastasis, which is responsible for 95% of cancer deaths.
1 out of 57 to 75 women will face ovarian cancer in her life just as Diem Brown did. [Ref. Target Ovarian Cancer and American Cancer Society]
Diem Brown, Amy Cohen Epstein and Paulinda Schimmel Babbini make their mission to educate women about ovarian cancer.
Diem Brown is the Founder and Visionnary of MedGift.com, Amy Cohen Epstein founded The Lynne Cohen Foundation for Ovarian Cancer Research, and Paulinda Schimmel Babbini created The Ovarian Cancer Circle/Inspired by Robin Babbini.
We have great credibility.
The research work behind this discovery was funded by the California Breast Cancer Research Program, Susan G. Komen for the Cure, National Cancer Institute, U.S. Department of Defense and National Institutes of Health. The National Cancer Institute recently awarded the company a grant for ovarian cancer.
The National Cancer Institute recognized the significance of our discovery and awarded us a grant last December. It will be used to test a new application of our drug to treat the form of ovarian cancer that is responsible for the deaths of most women who suffer from the disease: metastatic tumors in the abdomen.
The results we saw in our first study of this new application show great promise. Our scientists found that the new therapy eliminated all ovarian cancer metastatic tumors in the abdomen when tested in our laboratories.
This is very exciting news for two reasons.
It shows that if we can replicate the same results in human clinical trials, our discovery could reduce and possibly eliminate the pain, suffering, and death from this form of ovarian cancer.
It could change the current standard of care for women and substantially improve their quality of life. This is critical because the current standard of care very painful. Over 50% of women who receive it refuse to return for a second treatment.
Our impact in people's lives will be huge. 12-million people were diagnosed with cancer last year. This year 8-million people will lose their lives to cancer. The spread of cancer cells to other areas of the body will be responsible for over 95% of those cancer deaths. We can stop this.
The amount of funds raised that is listed to the right represents a number that includes general public donations and potential support of matching sponsors that Applied Integrin Sciences is in the process of inviting but has not secured yet.
With your Donations totalling $200,000
we will begin the work to prepare for human clinical trials.
Where we are: We have shown how effective and beneficial this new treatment can be.
Where we are going: With $200,000 in donations, we will demonstrate its so-called “drugability," where “drug discovery” becomes “drug development.”
With your donations totalling $500,000
we will have the drug manufactured under strict FDA guidelines - an important phase that all pharmaceutical companies need to do beforestarting human clinical trials.
With your donations totalling $1,000,000
we will fullfil the pre-requirements from FDA to file our Investigational New Drug Application with the FDA and this will allow us to begin human clinical trials to get the drug approved y FDA.
We found venture capitalists and pharmaceutical companies ready to step in once we are past this phase. We need your help now to jump-start this work.
AIS is a Socially Responsible Organization in Drug Development
Applied Integrin Sciences, Inc. discovers, develops and commercializes protein drug therapies for cancer treatments that reduce solid tumor growth and progression, and improve patient survival and quality of life. AIS is a socially responsible organization in drug development and targets the ovarian cancer indication for the intraperitoneal tumors as an orphan disease.
Our goal is to develop a treatment that significantly increases the standard of care for cancer. We understand that current treatment options are far from ideal and have as much negative impact on healthy cells as they do on cancer cells. Shortly after the patient is diagnosed with cancer, her quality of life is changed drastically. Aside from severe side effects of chemotherapy and invasive surgery, a patient is faced with an even greater and more debilitating fear that cancer will spread throughout the body, otherwise known as metastasis. A current treatment option for cancer that is no longer localized is not much different and involves additional chemotherapy, radiation, and more invasive surgery. Some patients, once diagnosed, with metastatic cancer lose hope and choose not to undergo further treatment. We want to prevent the progression of cancer, and in some cases prevent tumor growth in its localized form.
We have provided several documents that will tell you more about us and the novel treatment.
We have fabulous matching partners
We want to honor each one of your donated dollars. We are working hard at lining up many partners who will match your donation, dollar for dollar.
The amount of funds listed to the right represents a number that includes general public donations and potential support of matching sponsors that the organization is in the process of inviting but has not secured yet.